title: Targeting microtubules by natural agents for cancer therapy.
abstract: Natural compounds that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date. There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death. Our improved understanding of tumor biology and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer. The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance. Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs. Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer. This review focuses on the successful cancer chemotherapy from natural compounds in clinical settings and the challenges that may abort their usefulness.
authors.affiliation: Corresponding Author: Hasan Mukhtar, Department of Dermatology, University of Wisconsin-Madison, 410 Medical Sciences Center, 1300 University Avenue, Madison, WI 53706. hmukhtar@wisc.edu.
authors.forename: Eiman
authors.initials: E
authors.lastname: Mukhtar
authors.forename: Vaqar Mustafa
authors.initials: VM
authors.lastname: Adhami
authors.forename: Hasan
authors.initials: H
authors.lastname: Mukhtar
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D006801:Humans; D008870:Microtubules / Q000378:metabolism*; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products; D050257:Tubulin Modulators